Acer Therapeutics — Opexa Therapeutics — Corporate Update (November 2015)
62 slides from Acer Therapeutics's corporate update, Nov 10, 2015
Slide 1: Precision Immunotherapy
Precision Immunotherapy®
Slide 2: Forward-Looking Statements
@ OPEXA THERA Forward-Looking Statements All statements in this presentation other than those of historical fact, including statements regarding our preclinical and clinical development plans for Tcelna® and OPX-212, our research and other development programs, our ability to undertake certain activ
Slide 3: Agenda
Agenda 5:15-5:20 PM Welcome 5:20-5:40 PM Opexa Corporate Update — Neil Warma, CEO & Don Healey, CSO + Multiple Sclerosis Program + Neuromyelitis Optica (NMO) Preclinical Program + NMO Bioactivity Study Data 5:40-6:00 PM Dr. Clyde Markowitz — MS program & Abili-T Trial for Secondary Progressive MS 6:
Slide 4: Clyde Markowitz, M.D.
@ OPEXA Clyde Markowitz, M.D. + Associate Professor of Neurology at the Hospital of The University of Pennsylvania + Expert in the field of MS involved with many clinical trials developing new compounds for the treatment of MS + Director of the MS Center at the University of Pennsylvania and Profess
Slide 5: Benjamin Greenberg, M.D., M.H.S.
Benjamin Greenberg, M.D., M.H.S. + Associate Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology and Neurotherapeutics at UT Southwestern Medical Center * Internationally recognized expert in treating adults and children with rare autoimmune disorders of the ce
Slide 6: Opexa Investment Highlights
Opexa Investment Highlights > PIPELINE + Tcelna®: Phase 2b for secondary progressive multiple sclerosis (SPMS), limited competition, $7BN overall market potential + OPX-212: Pre-IND for neuromyelitis optica (NMO), no approved therapies, orphan indication > TECHNOLOGY + Personalized T-cell immunother
Slide 7: Recent and Upcoming Expected Milestones
@ OPEXA Recent and Upcoming Expected Milestones Tcelna: Multiple Sclerosis Y¥ Q3 2015: 92% of all patient visits in Abili-T trial have been completed Y¥ Q3 2015: The independent Data and Safety Monitoring Board (DSMB) overseeing Opexa’s Abili-T trial met and recommended the trial continue as planned
Slide 8: Recent and Upcoming Expected Milestones
@ OPEXA Recent and Upcoming Expected Milestones IP VY Q3 2015: Four additional key patents issued covering T-cell immunotherapy platform Y 160 total granted U.S. and international patents in Opexa’s patent portfolio, including in-licensed patents Financial (as of Sept 30, 2015) + ~$15.6 million cash
Slide 9: Tcelna in Secondary Progressive MS
Tcelna in Secondary Progressive MS 450,000 Individuals in North America diagnosed with MS; 30-45 % potentially have an SPMS diagnosis + Secondary Progressive MS market potential in North America could exceed $7 billion (for all therapies) + Roughly 150,000 SPMS patients in North America + Only one d
Slide 10: Tcelna
Tcelna® Lead Program Targeting Secondary Progressive MS patients Fast Track Designation by FDA * Phase 2b is fully enrolled: 190 patients with SPMS + Top line data expected in 2H 2016 + Design — Double-blind, 1:1 randomized, placebo-controlled - 35 clinical sites in USA and Canada — Two annual cours
Slide 11: Merck Serono Agreement
Merck Serono Agreement Agreement signed 2013; strong potential partner + Option and License Agreement for worldwide rights to all Multiple Sclerosis indications, excluding Japan + If Merck Serono exercises option: — Merck Serono to fund Phase 3, pre-commercial and commercial activities — Opexa has p
Slide 12: Leveraging the T-Cell Platform: OPX-212 for Neuromyelitis Optica (NMO)
@ OPEXA THERAPEUTICS LEVERAGING THE T-CELL PLATFORM: OPX-212 FOR NEUROMYELITIS OPTICA (NMO)
Slide 13: OPX-212: Opexa's Orphan Disease Program
OPX-212: Opexa’s Orphan Disease Program + Neuromyelitis optica (NMO) isa rare or orphan autoimmune disease + Immune system cells and antibodies mistakenly attack and destroy myelin cells in the opticnerves and the spinal cord + Individuals with NMO develop opticneuritis, which causes pain in the eye
Slide 14: Opexa's Novel Approach; Priming the Immune System
@ OPEXA THERAPEUTICS OPEXA’S NOVEL APPROACH; PRIMING THE IMMUNE SYSTEM
Slide 15: Root cause of MS: Activated T-cells degrade myelin
Root cause of MS: Activated T-cells degrade myelin and damage myelin producing cells In MS patients, the faulty immune system is not able to prevent the attack of a small sub- population of myelin reactive T-cells (MRTC) MRTCs cross the blood brain barrier, enter the brain, and bind to antigen prese
Slide 16: Tcelna could address the root cause of MS
@ OPEXA THERAPEUTICS Tcelna could address the root cause of MS by preventing ‘Adapted by permission fromMscrrlan Publishers Lid: NATURE REVEWS IMMUNOLOGY 3, 83-482 (June 2003), copyright (2003) * Therapeuticdose of Tcelna (attenuated T-cell clones) is injected subcutaneously + Thistriggers an immune
Slide 17: Clinical evidence for Tcelna MoA
Clinical evidence for Tcelna MoA T-cell technology demonstrated a significant reduction in reactive T-cells (52 week study results of MS) Week 0 Week 5 Week 13 Week 21 Week 28 Week 52 * SS -10% -20% 2 30% a4 = 40% & = 50% BS} oi = = -70% 4 -80% ai + Results from Teelna dose ranging studies: : Y Publ
Slide 18: OPX-212: Bioactivity Study
@ OPEXA THERAPEUTICS OPX-212: BIOACTIVITY STUDY Precision Immunotherapy®
Slide 19: NMO Bioactivity animal study results
oe OPEXA NMO Bioactivity animal study results * Bioactivity study supports development of OPX-212 * Opexa’s T-cell technology suppresses an immune response in mice relevant to the immunopathology of NMO * Results statistically significant * Evidence from the bio-activity study, demonstrating the pot
Slide 20: NMO Bioactivity study rationale
oe OPEXA NMO Bioactivity study rationale + Hypothesis: Can immunotherapy with attenuated T-cells reduce a T-cell response to the Neuromyelitis Optica (NMO) associated autoantigen, aquaporin-4? + No animal model of NMO has been established that exhibits both endogenous T-cell dependent immunity and a
Slide 21: Bioactivity Study Protocol
BD ovexa riexavevnecs Bioactivity Study Protocol . Pri ith Harvest lymph EXPERIMENTAL Dose with Product AQP4 pepti Mle nodes for T-cell GROUPS response to AQP4 Dayo Day7 Day14 Day 24 Day 34 Vehiele Control QB vA Va Pd 7 = GEE sxiot agea-tev 6B Va f Va _ cas 1x10° ova-tev GB Va va sf = — Gam 0.3x10°
Slide 22: Results: Suppression of a T-cell response to Aquaporin-4
@ OPEXA Results: Suppression of a T-cell response to Aquaporin-4 ‘AQP4 peptide mediated T cell Protferation (CD25 *CTFR'™) oo § ag #8 ze 2 B . ’ ° bel ee sige eat |les] ae see eg * Pre-treatment of B6 Srcaar" Ger [eee car calay | Come cae aes Tee mice with Vewicecomel | tide O3e10doxe | ortfacse L01
Slide 23: Clyde Markowitz, M.D.
@ OPEXA THERAPEUTICS Clyde Markowitz, M.D. Associate Professor of Neurology at the Hospital of The University of Pennsylvania Precision Immunotherapy®
Slide 24: Abili-T Trial: SPMS Design
@ OPEXA THERAPEUTICS ABILI-T TRIAL: SPMS DESIGN Precision Immunotherapy®
Slide 25: Abili-T Trial: SPMS Design
Abili-T Trial: SPMS Design Fast Track designation granted by FDA + Abili-T Phase IIb clinical trial is ongoing — Double-blind, 1:1 randomization, placebo-controlled — Subjects with Secondary Progressive MS — EDSS of 3.0 to 6.0 — Immune Monitoring program * 190 Subjects enrolled — 35 sites in USA and
Slide 26: Two Year Dosing Regimen
Two Year Dosing Regimen Sern Sem Baseline Wk4 Wk8 Wk12 WK24 Wk 36 Wk 52 eos 5S = cere = zs 2-1m :
Slide 27: Outcome Measures
@ OPEXA THERAPEUTICS OUTCOME MEASURES Precision Immunotherapy® 27
Slide 28: Efficacy Assessments
Efficacy Assessments Primary Endpoint: = Percent of whole-brain atrophy * Brain atrophy is a clinically relevant and robust component of disease progression in MS = Measurement of axonal loss; rate of axonal loss is ~0.5%/yr “ Progressive whole-brain atrophy can be detected in vivo in a sensitive an
Slide 29: Efficacy Assessments (cont.)
Efficacy Assessments (cont.) Key Secondary Endpoints: = Sustained progression measured by EDSS = Composite endpoint that includes = EDSS increase sustained for 12 weeks, or = A 20% increase in time, sustained for 24 weeks, in one of the following changes in disability: » Timed 25 Foot Walk (T25FW) a
Slide 30: Supportive Brain Atrophy Data for ARR>1 from TERMS study
Supportive Brain Atrophy Data for ARR>1 from TERMS study + TERMS was a Phase IIb study of Tcelna in relapsing remitting MS patients completed in 2008 + Although TERMS did not show statistical significance in its primary endpoint (cumulative number of GdE lesions determined by MRI), it did show compe
Slide 31: Previous Opexa SPMS Data
@ OPEXA THERAPEUTICS PREVIOUS OPEXA SPMS DATA
Slide 32: SPMS Patient Data: Previous Studies
SPMS Patient Data: Previous Studies Tcelna stabilizes disease in SPMS Patients at 2 years 80% of patients showed no further disease progression by EDSS at 2 years Stabilization vs. Historical Progression e) 100% g g $ 2 a 30% ? 80% Fa A Stable B= 60% 3 § @Progressed 2: == br 2 40% Ba 40% . 2 2 20% 5
Slide 33: Tcelna Reduces Annualized Relapse Rate in SPMS at 2 years
@ om Tcelna Reduces Annualized Relapse Rate (ARR) in SPMS at 2 years Annualized Relapse Rate (ARR) Tcelna treated SPMS patients (n=10) 0.60 0.50 In 21.8 years of cumulative 0:49 patient follow up, only 1 0.30 patient experienced 1 relapse 0.20 0.10 0.00 Baseline 12 Months 24 Months One relapse obser
Slide 34: Tcelna Stabilizes Quality of Life Scores in SPMS at 2 years
OPEXA THERAPEUTICS Tcelna Stabilizes Quality of Life Scores in SPMS at 2 years 2 3 3 ZB 4.0% 3 = Tcelna treated Tcelna treated = ‘m=10) n=7, 2 20% on eo? g 7 Physical 2 0.0% 4 3 «Psychological El 2 EB -2.0% 3 % £ 5 3 S -4.0% & 3 5 2 . Negative percent change indicates eg 6% ‘improvement frombaseline
Slide 35: Tcelna: The Story
@ OPEXA THERAPEUTICS TCELNA®: THE STORY Precision Immunotherapy®
Slide 36: Secondary Progressive MS
Secondary Progressive MS Patients initially experience a relapsing-remitting course then transition to SPMS AA Time Rolapsing-remiting Dicabilty ‘Secondary progressive (folowing relapsing-remiting) SPMS patients experience worsening disability i with or without relapses i Pe Time Time Oisabity rimar
Slide 37: The Immunopathology of SPMS: Relevance of Tcelna
@ over The Immunopathology of SPMS: Relevance of Tcelna * Compartmentalized CNS inflammatory cells — Persistence of meningeal mononuclear cell infiltrates associated in lymphoid follicular structures - Microglia activation suggests ongoing chronic innate immune responses * Meningeal follicles close
Slide 38: Proposed Mechanism
OPEXA < Proposed Mechanism + Attenuated, patient-specific (autologous) myelin reactive T-cells (MRTC) — MRTC expanded ex vivo in response to immunodominant peptides of MBP, MOG & PLP * Therapeutic SubQ dosing (30-45 x 10° cells) stimulates host reactivity to the ‘over-represented’ MRTC inducing a do
Slide 39: Tcelna: Promising Efficacy For SPMS
Tcelna: Promising Efficacy For SPMS + Previous studies have shown: — Favorable safety — Well tolerated treatment — Promising efficacy trend in atrophy and progression * Utilizing meaningful endpoints — Predicable measurements; atrophy by MRI — Acceptable by FDA; composite progression endpoint + Pers
Slide 40: Ben Greenberg, M.D., M.H.S.
@ OPEXA THERAPEUTICS BEN GREENBERG, M.D., M.H.S. Associate Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology and Neurotherapeutics at UT Southwestern Medical Center Precision Immunotherapy®
Slide 41: OPX-212: Neuromyelitis Optica (NMO)
@ OPEXA THERAPEUTICS OPX-212: NEUROMYELITIS OPTICA (NMO) Precision Immunotherapy®
Slide 42: Understanding Neuromyelitis Optica (NMO) in the Context of MS
‘ee OPEXA THERAPEUTIC Understanding Neuromyelitis Optica (NMO) in the Context of MS 27 year old woman presentsto an ER with 24 hours of difficulty urinating. A foley is placed and one liter of, urine is drained from her bladder. Within 12 hours she became weak and ultimately had no motor control of
Slide 43: Identifying a Biomarker
Identifying a Biomarker
Slide 44: Defining the Molecular Basis of Neuromyelitis Optica
@ OPEXA Defining the Molecular Basis of Neuromyelitis Optica * Identify the target of the NMO IgG + Determine how the biology of the antigenic target relates to the phenotype + Determine the upstream and downstream components of the disease —- Antibody mediated tissue destruction versus functional m
Slide 45: & a = a w s co ro} r YOBwO}S
& a = a w s co ro} 2 r 5 3 YOBwO}S
Slide 46: Therapeutic Landscape in NMO
Therapeutic Landscape in NUO * No FDA approved therapies + All off label use medications are immunosuppressive * Unique risk-benefit calculations when immunosuppressive is used * Therapies are universally targeting the B cell mediated component of the condition 46
Slide 47: Pathways/Treatments being Investigated
@ OPEXA Pathways/Treatments being Investigated + Anti-AQP4 binding interference —- Small molecule — Binding competition + B-cell depletion therapy * Complement inhibition ¢ IL6 inhibition (anti-IL6R) * Therapies that interfere with granulocyte recruitment * Future therapies should be based on biolog
Slide 48: Unmet Needs: NMO as a T-cell Mediated Condition
@ OPEXA THERAPEUTICS Unmet Needs.... NMO AS A T-CELL MEDIATED CONDITION
Slide 49: Role for T-cells in Neuromyelitis Optica
Role for T-cells in Neuromyelitis Optica 1. T cell-activation in neuromyelitis optica lesions plays a role in their formation. Pohl, M et al. Acta Neuropathol Commun. 201331:85. Immunology of neuromyelitis optica: a T cell-B cell collaboration. Mitsdoerffer, M et al. Ann N Y Acad Sci. 2013;1283:57-6
Slide 50: Disease Pathogenesis
Disease Pathogenesis @ wisarierssienes An astrocytopathic disease of the CNS characterized by optic neuritis, transverse myelitis; it is a B-cell-dependent disease associated with — antibodies | PathogenicT-Cells_| ¥ Inflammatory Cells Plasma Cell me (D4 T-cell CD6g__ nftration of N ee smacrophagesa
Slide 51: Potential Intervention Points for T-cell Therapy
OPEXA THERAPEUTICS Potential Intervention Points for T-cell Therapy T-cell therapy believed to inhibit AQP-4 autoantibody, pro-inflammatory cytokines and prevent infiltration of macrophages and granulocytes Pathogenic T-Cells ~ [opx-s:2 | ‘ted toprevent OPX-212 expected todown —— tration of regulate
Slide 52: Meeting unmet needs
Meeting unmet needs Potentially useful for seropositive and seronegative patients ¢ Antigen specific Personalized medicine ¢ Not overtly immunosuppressive......... This could potentially change the risk/ benefit calculation dramatically for patients
Slide 53: Draft OPX-212.201 Clinical Plan
Draft OPX-212.201 Clinical Plan* * Open-label 3 arm dose escalation study * Subjects diagnosed with NMSD; + anti-AQP4-Ig * 20 week treatment period (5 doses: BL, Wk 4, 8, 12, 20) * 28 week follow up period (48 wk duration) + Endpoints: safety, reduction in ARTCs * Estimated first subject enrolled in
Slide 54: Back to Neil
BACK TO NEIL
Slide 55: Recent and Upcoming Expected Milestones
@ OPEXA Recent and Upcoming Expected Milestones Tcelna: Multiple Sclerosis Y¥ Q3 2015: 92% of all patient visits in Abili-T trial have been completed Y¥ Q3 2015: The independent Data and Safety Monitoring Board (DSMB) overseeing Opexa’s Abili-T trial met and recommended the trial continue as planned
Slide 56: Recent and Upcoming Expected Milestones
@ OPEXA Recent and Upcoming Expected Milestones IP VY Q3 2015: Four additional key patents issued covering T-cell immunotherapy platform Y 160 total granted U.S. and international patents in Opexa’s patent portfolio, including in-licensed patents Financial (as of Sept 30, 2015) + ~$15.6 million cash
Slide 57: Opexa Investment Highlights
Opexa Investment Highlights > PIPELINE + Tcelna®: Phase 2b for secondary progressive multiple sclerosis (SPMS), limited competition, $7BN overall market potential + OPX-212: Pre-IND for neuromyelitis optica (NMO), no approved therapies, orphan indication > TECHNOLOGY + Personalized T-cell immunother
Slide 58: Questions & Answers
@ OPEXA THERAPEUTICS QUESTIONS & ANSWERS Precision Immunotherapy®
Slide 59: Appendix
APPENDIX
Slide 60: Phase 2b RRMS prior clinical trial
Phase 2b RRMS prior clinical trial BD orrnoe Tcelna showed 37% improvement over placebo (mITT) (secondary endpoint measurement, primary MRI endpoint measure not met) 37% Reduction in Annualized Relapse Rate (ARR) 0.4 0.35 = § 03 eS 37% aTcelna £ 0.2! 3°° @ Placebo S ay oF 0.214 z n=142 Q os a So m 0
Slide 61: Experienced Management Team and Board of Directors
(GB) crea rice Experienced Management Team and Board of Directors Neil Warma, President & CEO, Director > 19+ years intemational healthcare experience with large Pharma and emerging Board of Directors biotechnology companies > Former Senior Management, Novartis Pharmaceuticals, Basel, Switzerland im
Slide 62: SPMS Scientific Advisory Board
SPMS Scientific Advisory Board > Dawn McGuire, M.D., FAAN (Chair) + Advisory Council of the Gill Heart Institute + Former Vice President of Clinical Research at Elan Pharmaceuticals Hans-Peter Hartung, M.D + Chair of Neurology at Heinrich-Heine University, Diisseldorf + Executive Board member of ECT
Opexa Therapeutics — Corporate Update (November 2015) on 6ix